• Merck will continue to investigate opportunities to reduce the cost of our antiretrovirals for people living in the world’s poorest countries and those hardest hit by the pandemic, including through partnering with external manufacturers and suppliers to achieve incremental efficiencies.
• As emerging markets become a more central part of Merck’s business strategy, we will continue to investigate new business models to drive our revenue growth in these markets moving forward, while also ensuring access.
• We remain committed to continued R&D investment in new treatments for HIV.

The content on this page was last modified on September 15, 2009.

Merck & Co., Inc., Whitehouse Station, NJ, USA, and Schering-Plough Corporation, Kenilworth, NJ, USA, are now one company. We have combined our global operations under the name Merck & Co., Inc. We are working to update our corporate responsibility Web site to reflect our new, combined, global organization.